Mounjaro, Wegovy or the Wegovy pill: which is right for you

Mounjaro (tirzepatide), Wegovy (semaglutide injection) and the Wegovy pill (oral semaglutide) are the three GLP-1 medications we most often prescribe for weight management. Mounjaro and Wegovy are once-weekly injections; the Wegovy pill is a daily tablet. All three will work for the patients they are right for, and all three sit on our menu as first-line options rather than first-and-second-best.

A note on the regulatory framing. All three carry a UK weight-management licence from the MHRA. The Wegovy pill (oral semaglutide 25mg) was licensed for weight loss in June 2026, the first oral GLP-1 approved for weight in the UK.

The choice between the three depends on factors we work through together in your first consultation. This article explains what is actually different, and how we make the call.

Effectiveness

This is the question everyone asks first. In the largest head-to-head trials (SURPASS-2, SURMOUNT, STEP and PIONEER programmes):

Mounjaro at its maximum 15mg dose produces an average weight loss of around 22.5 percent of starting body weight after 72 weeks of treatment.

Wegovy at 2.4mg produces an average weight loss of around 15 percent over the same period. The newer 7.2mg Wegovy dose (MHRA-approved January 2026) achieves 20.7 percent.

The Wegovy pill at its full 25mg daily dose produces an average weight loss of around 16.6 percent over about 15 months in trials, with a third of people losing 20 percent or more. That puts the licensed tablet close to the injectables.

Only about 0.4 to 1 percent of each oral dose survives stomach acid and reaches the bloodstream; the injectables deliver the medication directly. The licensed Wegovy pill makes up for the low absorption with a higher dose, so it is no longer the lower-yield option it once was. Mounjaro, which works on a second hormone too, still produces the most weight loss; the choice between the Wegovy injection and the Wegovy pill is mostly whether you prefer a weekly jab or a daily tablet.

Side effect profile

All three share the same family of side effects, dominated by gastrointestinal upset during titration. Nausea, constipation, and occasional vomiting affect most patients at some point in the first twelve weeks and then settle.

There are some differences that matter for specific patients.

Wegovy tends to have marginally more reports of nausea at comparable effectiveness doses.

Mounjaro tends to have marginally more reports of mild diarrhoea or loose stool.

Early on, at the low starting doses, the Wegovy pill is gentler; at the full 25mg dose its GI side effects are similar to the injectables. Nausea and constipation are the most common on all of them.

All three share the small but real risks of gallstone disease, pancreatitis, and thyroid C-cell tumours (the last of which has only been demonstrated in rats, not in humans, but is still included as a theoretical contraindication in patients with a personal or family history of medullary thyroid cancer or MEN2).

If you have a sensitive stomach or a history of reflux, the choice between the three is often decided by which side effect profile you would rather work with.

Cost

UK private pricing varies significantly by provider. The underlying list prices from the manufacturers matter:

Mounjaro (Eli Lilly) list price rose sharply in September 2025. At LoveMyLife, Mounjaro ranges from £164.99 (2.5mg) to £316.99 (15mg).

Wegovy (Novo Nordisk) pricing has been more stable. At LoveMyLife, Wegovy is from £149.99 a month.

At LoveMyLife the medication is billed separately, at one transparent price that is the same whichever of the three you are on and whichever route you choose. If you stay with us, a monthly care fee covers your reviews, dose changes, messaging and delivery. Dose escalations do not change that care fee.

Availability and supply

The injectables have been subject to intermittent supply disruption over the last two years, particularly at starting doses. We keep advance visibility of supply. If one medication is difficult to source we will tell you honestly and switch you or start you on another, rather than leaving you waiting for three weeks.

Cardiovascular evidence

This matters if you have existing cardiovascular risk factors.

Semaglutide (the active ingredient in both the Wegovy injection and the Wegovy pill) has specific evidence from the SELECT trial showing cardiovascular benefit in people with pre-existing cardiovascular disease and overweight or obesity. The MHRA licence for Wegovy now includes a cardiovascular benefit indication. The Wegovy pill is the same active ingredient and inherits a strong body of cardiovascular safety data from oral semaglutide's type 2 diabetes use.

Tirzepatide's equivalent cardiovascular outcome trial (SURPASS-CVOT) is ongoing. Early signals are consistent with benefit, but the formal cardiovascular benefit indication has not yet been granted in the UK.

If you have had a heart attack, stroke, or documented coronary artery disease, a semaglutide-based option (the Wegovy injection or the Wegovy pill) is currently the more conservative evidence-based choice.

Diabetes and pre-diabetes

If you have type 2 diabetes or significant pre-diabetes:

Mounjaro has the stronger glycaemic effect. HbA1c reductions on Mounjaro are typically 1.5-2.0 percent at maintenance dose, compared with 1.0-1.5 percent for semaglutide.

The Wegovy injection and the Wegovy pill both deliver semaglutide; the HbA1c effect of the injection is slightly stronger than the tablet at currently licensed doses.

If your main goal is weight loss but your HbA1c is also in the 42-50 mmol/mol pre-diabetic range, Mounjaro gives you the dual benefit, with Wegovy a close second.

How you want to take the medication

This is the question that matters most after effectiveness, and the one patients often arrive without having thought about.

Wegovy and Mounjaro: one self-administered injection a week, taken on the same day each week, any time of day, with or without food. Most patients find injections far less difficult than they expected; the pen needles are very small.

The Wegovy pill: one tablet every morning, on an empty stomach with no more than 120ml of plain water, at least 30 minutes before eating or drinking anything else. That window must be protected every day. If your morning routine includes coffee before brain-on, the Wegovy pill is hard.

A weekly injection demands less of your day-to-day routine than a daily tablet with a fasting window. A daily tablet demands no injection. Different lives suit different rhythms.

How we make the decision with you

In your first consultation we work through:

Your weight-loss goal and starting BMI.

Your cardiovascular risk (established disease or risk factors).

Your HbA1c.

Your personal and family medical history (thyroid, pancreatitis, gallstones).

Your tolerance for an injection and your morning routine.

Your preferences and any prior experience with these medications.

Your budget and whether you are paying for all twelve months up front or month by month.

In most cases more than one of the three is reasonable. Our common starting points: for patients with BMI over 30 and no specific contraindication, Mounjaro at 2.5mg with planned escalation; for patients with established cardiovascular disease, Wegovy; for patients who would rather take a daily tablet than inject, the Wegovy pill. For patients who have tried one and not tolerated it, we switch to one of the others.

You are not locked in

Switching between the three during treatment is straightforward. If you start on Mounjaro and want to switch to Wegovy or the Wegovy pill after three months, we do that at your next review with no additional assessment charge. All three are dispensed by us, so the switch happens in days, not weeks.

Begin your assessment with our weight management doctors.

Ready to start?

If this article has made you think medication might help, the next step is a short consultation with one of our weight-management doctors.

Begin your assessment at this link. Online in 30 minutes, or in person at Westfield London.